Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216993 | PMC |
| http://dx.doi.org/10.1038/s41375-024-02260-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenetics in hematopathology and hematology: why a common language is important.
Leukemia
July 2024
IMGT®, the international ImMunoGeneTics information system®, Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France.
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
Blood
April 2024
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Monoclonal B-cell lymphocytosis (MBL) progresses to chronic lymphocytic leukemia (CLL) requiring therapy at 1% to 5% per year. Improved prediction of progression would greatly benefit individuals with MBL. Patients with CLL separate into 3 distinct epigenetic subtypes (epitypes) with high prognostic significance, and recently the intermediate epitype has been shown to be enriched for high-risk immunoglobulin lambda variable (IGLV) 3-21 rearrangements, impacting outcomes for these patients.
View Article and Find Full Text PDFNatural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
HLA
February 2022
Department of Immunology, Hospital Clínic, Barcelona, Spain.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm treated with tyrosine kinase inhibitors (TKIs). Although survival rates have improved, response to these treatments is highly heterogeneous. Variations in response rates may be due to different causes such as, treatment adherence, mutations in the BCR-ABL1 gene, clonal evolution and amplification of the BCR-ABL1 gene, but innate immune response is also considered to play a very important role and, specifically, NK cell activity through their receptors and ligands, could be determinant.
View Article and Find Full Text PDFChronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.
Haematologica
September 2020
Hematopathology Section, Hospital Cllinic, University of Barcelona, Barcelona, Spain.
Chronic lymphocytic leukemia is a well-defined lymphoid neoplasm with very heterogeneous biological and clinical behavior. The last decade has been remarkably fruitful in novel findings elucidating multiple aspects of the pathogenesis of the disease including mechanisms of genetic susceptibility, insights into the relevance of immunogenetic factors driving the disease, profiling of genomic alterations, epigenetic subtypes, global epigenomic tumor cell reprogramming, modulation of tumor cell and microenvironment interactions, and dynamics of clonal evolution from early steps in monoclonal B cell lymphocytosis to progression and transformation into diffuse large B-cell lymphoma. All this knowledge has offered new perspectives that are being exploited therapeutically with novel target agents and management strategies.
View Article and Find Full Text PDFDisease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations.
J Pathol
April 2019
Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.
The B cell receptor immunoglobulin (Ig) gene repertoires of marginal zone (MZ) lymphoproliferations were analyzed in order to obtain insight into their ontogenetic relationships. Our cohort included cases with MZ lymphomas (n = 488), i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!